| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (NCT05335993) | CanariaBio Inc. | 2022-07-25 |
| Niraparib Plus Anlotinib for Recurrent Ovarian Cancer (NCT05311579) | Lei Li | 2022-03-27 |
| A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer (NCT04718740) | Jiangsu HengRui Medicine Co., Ltd. | 2021-06-25 |
| Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer (NCT04457089) | Marc Goodman | 2021-01-25 |
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03776812) | Corcept Therapeutics | 2019-04-05 |
| Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer (NCT03632798) | Cordgenics, LLC | 2018-08-01 |
| Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (NCT03564340) | Regeneron Pharmaceuticals | 2018-05-21 |
| Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer (NCT03430518) | Amy Tiersten | 2018-05-17 |
| Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer (NCT02849353) | Fuda Cancer Hospital, Guangzhou | 2016-07-01 |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer (NCT02788708) | Floor Backes | 2016-05-27 |
| A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer (NCT02737787) | Memorial Sloan Kettering Cancer Center | 2016-04-01 |
| Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer (NCT02117817) | Rutgers, The State University of New Jersey | 2015-02-01 |
| Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer (NCT02303912) | Imperial College Healthcare NHS Trust | 2014-11-01 |
| Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer (NCT02195973) | University of Alabama at Birmingham | 2014-09-01 |
| LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma (NCT02083536) | University of Miami | 2014-05-01 |
| H.O.P.E: Helping Ovarian Cancer Patients Cope (NCT02090582) | Duke University | 2014-04-01 |
| Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment (NCT02035345) | Massachusetts General Hospital | 2014-01-01 |
| Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer (NCT01802749) | National Cancer Institute, Naples | 2013-11-01 |
| An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer (NCT01869400) | PharmaMar, Spain | 2013-04-01 |
| A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer (NCT01851746) | Wuhan University | 2013-03-01 |
| Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer (NCT01809379) | Ruhr University of Bochum | 2013-02-01 |
| Interactive Educational Website for Women With Ovarian Cancer & Caregivers (NCT01626014) | University of Minnesota | 2012-08-01 |
| Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer (NCT01639885) | Leiden University Medical Center | 2011-08-01 |
| Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (NCT01381861) | Tracon Pharmaceuticals Inc. | 2011-07-01 |
| Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer (NCT01637532) | Leiden University Medical Center | 2011-02-01 |
| Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer (NCT03025867) | Tesaro, Inc. | |